Kaplan-Meier curves for effects of SCT and selected comutations. (A) Effect of SCT in CR1 (n = 45) on OS (35.4 months vs not reached; P = .009). (B) Effect of SCT in CR1 on EFS (16.1 months vs not reached; P = .0002). (C) Effect of combined FLT3-ITD and DNMT3A mutations (n = 22) on EFS in comparison with cases with FLT3-ITD⁻/DNTM3A⁺, FLT3-ITD⁺/DNMT3A⁻, or FLT3-ITD⁻/DNMT3A⁻ (6.6 vs 25.8 months; P = .029), censoring patients at the time of SCT. (D) Effect of either KRAS or NRAS mutation (n = 30) on EFS (16.3 vs 32.4 months; P = .044), censoring patients at the time of SCT.